Results of a study to measure the effectiveness of the drug Solifenacin in the treatment of overactive bladder problems were presented last week.
The Study was led by Professor Linda Cardozo from the Department of Urogyneacology at King’s College in London. Over a hundred urology centres from 14 countries took part in the study.
In total 863 patients took part in a 16 week double blind randomised study, where neither the researchers nor patients were aware of which were taking the placebo or the drug.
Results showed a reduction of 70 percent in severe urgency and urgency with incontinence compared to 50 percent for those taking placebo.
There were also significant improvements in all levels of urgency, maximum urgency intensity and urgency bother.
This was the first study to use urgency as an endpoint using the Patient Perception of Intensity Scale (PPIUS); this scale ranges from zero to four with grades 3 and 4 representing urgency and urgency incontinence.
Professor Cardozo concluded:
“Our study found that Solifenacin was consistently effective at reducing urgency and other symptoms associated with an overactive bladder and that simple scoring scales, such as the PPIUS, are a reliable way of measuring treatment outcome.”
Solifenacin (rINN), marketed as Solifenacin succinate under the trade name Vesicare, is a urinary antispasmodic of the anticholinergic class. It is used in the treatment of overactive bladder with or without urge incontinence.
Results of a study to measure the effectiveness of the drug Solifenacin in the treatment of overactive bladder problems were presented last week.
The Study was led by Professor Linda Cardozo from the Department of Urogyneacology at King’s College in London. Over a hundred urology centres from 14 countries took part in the study.
In total 863 patients took part in a 16 week double blind randomised study, where neither the researchers nor patients were aware of which were taking the placebo or the drug.
Results showed a reduction of 70 percent in severe urgency and urgency with incontinence compared to 50 percent for those taking placebo.
There were also significant improvements in all levels of urgency, maximum urgency intensity and urgency bother.
This was the first study to use urgency as an endpoint using the Patient Perception of Intensity Scale (PPIUS); this scale ranges from zero to four with grades 3 and 4 representing urgency and urgency incontinence.
Professor Cardozo concluded:
Solifenacin (rINN), marketed as Solifenacin succinate under the trade name Vesicare, is a urinary antispasmodic of the anticholinergic class. It is used in the treatment of overactive bladder with or without urge incontinence.